Pharmaceutical company, Biocodex, is developing a new oral-suspension formulation for DIACOMIT, an FDA-approved treatment indicated for the management of seizures associated with Dravet syndrome.
Dravet syndrome is a rare and severe genetic epilepsy that most commonly begins before the age of one when an otherwise normally developing child begins having frequent, prolonged seizures.
These seizures can cause lasting damage, which over time can lead to developmental and cognitive delays, affecting coordination, language, and behaviour. Its incidence is estimated to be 1 in 16,000 births.
This new formulation will be indicated for patients six months and older taking clobazam. Biocodex’s Research and Development (R&D) centre in France is developing this latest innovation, which represents a significant advancement for young patients suffering from this rare, severe, and treatment-resistant form of epilepsy.
“At Biocodex Orphan, our priority is to improve the quality of life for children affected by Dravet syndrome and their families at every stage of comprehensive care,” said Caroline Schreiner, Vice President of Global Orphan Diseases at Biocodex.
“This new development is a concrete testament to our commitment to providing innovative solutions tailored to children suffering from this syndrome.”
DIACOMIT is an approved Dravet specific treatment, available in over 55 countries. Currently offered in capsules and sachets formats, DIACOMIT will be available as an oral suspension, a formulation better suited to the needs of younger patients, especially infants with low body weight, those who cannot swallow capsules, or require precise dose adjustments.
